Back
Return
Biography
Prof. Tadeusz Robak

Prof. Tadeusz Robak

Department of Hematology, Medical University of Lodz

Copernicus Memorial Hospital, 93-510 Lodz, Ul. Ciolkowskiego 2, Poland

 

Email: robaktad@csk.umed.lodz.pl

 

Qualifications

1993 Professor, Medical University of Lodz, Poland

1979 Ph.D., Medical University of Lodz, Poland

1973 M.D., Medical University of Lodz, Poland

 

Publications (Selected)

  1. Li J, Zhi J, Wenger M, Valente N, Dmoszynska A, Robak T, Mangat R, Joshi A, Visich J. Population Pharmacokinetics of Rituximab in Patients With Chronic Lymphocytic Leukemia. J Clin Pharmacol. 2012 Jan 10.
  2. Pluta P, Smolewski P, Pluta A, Cebula-Obrzut B, Wierzbowska A, Nejc D, Robak T, Kordek R, Gottwald L, Piekarski J, Jeziorski A. Significance of bax expression in breast cancer patients. Pol Przegl Chir. 2011 Oct 1; 83(10): 549-53.
  3. Kantarjian HM, Shah NP, Cortes JE, Baccarani M, Agarwal MB, Undurraga MS, Wang J, Kassack Ipiña JJ, Kim DW, Ogura M, Pavlovsky C, Junghanss C, Milone JH, Nicolini FE, Robak T, Van Droogenbroeck J, Vellenga E, Bradley-Garelik MB, Zhu C, Hochhaus A. Dasatinib or imatinib in newly diagnosed chronic phase chronic myeloid leukemia: 2-year follow-up from a randomized phase 3 trial (DASISION). Blood. 2011 Dec 9.
  4.  Kropff M, Giongco-Baylon H, Hillengass J, Robak T, Hajek R, Liebisch P, Goranov S, Hulin C, Blade J, Caravita T, Avet-Loiseau H, Moehler TM, Pattou C, Lucy L, Kueenburg E, Glasmacher A, Zerbib R, Facon T. Thalidomide versus dexamethasone for the treatment of relapsed and/or refractory multiple myeloma: results from OPTIMUM, a randomized trial. Haematologica. 2011 Dec 1.
  5. Eichhorst B, Dreyling M, Robak T, Montserrat E, Hallek M; ESMO Guidelines Working Group. Chronic lymphocytic leukemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2011 Sep; 22 Suppl 6: vi50-4.
  6. Elter T, Gercheva-Kyuchukova L, Pylylpenko H, Robak T, Jaksic B, Rekhtman G, Kyrcz-Krzemień S, Vatutin M, Wu J, Sirard C, Hallek M, Engert A. Fludarabine plus alemtuzumab versus fludarabine alone in patients with previously treated chronic lymphocytic leukaemia: a randomised phase 3 trial. Lancet Oncol. 2011 Dec; 12(13): 1204-13.
  7. Smolewski P, Robak T. Inhibitors of Apoptosis Proteins (IAPs) as Potential Molecular Targets for Therapy of Hematological Malignancies. Curr Mol Med. 2011 Dec 1; 11(8): 633-49.
  8. Szmigielska-Kaplon A, Robak T. Hypomethylating agents in the treatment of myelodysplastic syndromes and myeloid leukemia. Curr Cancer Drug Targets. 2011 Sep 1; 11(7): 837-48.
  9. Pluta P, Cebula-Obrzut B, Ehemann V, Pluta A, Wierzbowska A, Piekarski J, Bilski A, Nejc D, Kordek R, Robak T, Smolewski P, Jeziorski A. Correlation of Smac/DIABLO protein expression with the clinico-pathological features of breast cancer patients. Neoplasma. 2011; 58(5): 430-5.
  10. Robak T. Management of hairy cell leukemia variant. Leuk Lymphoma. 2011 Jun; 52 Suppl 2: 53-6.
  11. Crowther-Swanepoel D, Di Bernardo MC, Jamroziak K, Karabon L, Frydecka I, Deaglio S, D'Arena G, Rossi D, Gaidano G, Olver B, Lloyd A, Broderick P, LaurentiL, Szemraj-Rogucka Z, Robak T, Catovsky D, Houlston RS. Common genetic ariation at 15q25.2 impacts on chronic lymphocytic leukaemia risk. Br J Haematol. 2011 Jul; 154(2): 229-33.
  12. Moreau P, Pylypenko H, Grosicki S, Karamanesht I, Leleu X, Grishunina M, Rekhtman G, Masliak Z, Robak T, Shubina A, Arnulf B, Kropff M, Cavet J, Esseltine DL, Feng H, Girgis S, van de Velde H, Deraedt W, Harousseau JL. Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority study. Lancet Oncol. 2011 May; 12(5): 431-40. Epub 2011 Apr 18. Erratum in: Lancet Oncol. 2011 Jun; 12(6): 522.
  13. Bladé J, Sonneveld P, San Miguel JF, Sutherland HJ, Hajek R, Nagler A, Spencer A, Robak T, Lantz KC, Zhuang SH, Harousseau JL, Orlowski RZ; DOXIL-MMY-3001 Study Investigators. Efficacy and safety of pegylated liposomal Doxorubicin in combination with bortezomib for multiple myeloma: effects of adverse prognostic factors on outcome. Clin Lymphoma Myeloma Leuk. 2011 Feb; 11(1): 44-9.
  14. Richardson P, Schlag R, Khuageva N, Dimopoulos M, Shpilberg O, Kropff M, Vekemans MC, Petrucci MT, Rossiev V, Hou J, Robak T, Mateos MV, Anderson K, Esseltine DL, Cakana A, Liu K, Deraedt W, van de Velde H, San Miguel JF. Characterization of haematological parameters with bortezomib-melphalan-prednisone versus melphalan-prednisone in newly diagnosed myeloma, with evaluation of long-term outcomes and risk of thromboembolic events with use of erythropoiesis-stimulating agents: analysis of the VISTA trial. Br J Haematol. 2011 Mar 6.
  15. Kotkowska A, Wawrzyniak E, Blonski JZ, Robak T, Korycka-Wolowiec A. Chromosomal aberrations in chronic lymphocytic leukemia detected by conventional cytogenetics with DSP30 as a single agent: comparison with FISH. Leuk Res. 2011 Aug; 35(8): 1032-8.
  16. Robak T, Szmigielska-Kapłon A, Pluta A, Grzybowska-Izydorczyk O, Wolska A, Czemerska M, Wierzbowska A. Novel and emerging drugs for acute myeloid leukemia: pharmacology and therapeutic activity. Curr Med Chem. 2011; 18(5): 638-66.
  17. Lech-Maranda E, Robak E, Robak T. Novel systemic drugs for cutaneous T-cell lymphoma. Recent Pat Anticancer Drug Discov. 2011 Jan; 6(1): 70-93. Review.
  18. Robak T, Robak E. New anti-CD20 monoclonal antibodies for the treatment of B-cell lymphoid malignancies. BioDrugs. 2011 Feb 1; 25(1): 13-25.
  19. Robak T, Mainau C, Pyringer B, Chojnowski K, Warzocha K, Dmoszynska A, Straub J, Imbach P. Efficacy and safety of a new intravenous immunoglobulin 10% formulation (octagam® 10%) in patients with immune thrombocytopenia. Hematology. 2010 Oct; 15(5): 351-9.
  20. Dornan D, Spleiss O, Yeh RF, Duchateau-Nguyen G, Dufour A, Zhi J, Robak T, Moiseev SI, Dmoszynska A, Solal-Celigny P, Warzocha K, Loscertales J, Catalano J, Afanasiev BV, Larratt L, Rossiev VA, Bence-Bruckler I, Geisler CH, Montillo M, Wenger MK, Weisser M. Effect of FCGR2A and FCGR3A variants on CLL outcome. Blood. 2010 Nov 18; 116(20): 4212-22.
  21. Whittaker SJ, Demierre MF, Kim EJ, Rook AH, Lerner A, Duvic M, Scarisbrick J, Reddy S, Robak T, Becker JC, Samtsov A, McCulloch W, Kim YH. Final results from a multicenter, international, pivotal study of romidepsin in refractory cutaneous T-cell lymphoma. J Clin Oncol. 2010 Oct 10; 28(29): 4485-91.
  22. Treliński J, Wierzbowska A, Krawczyńska A, Sakowicz A, Pietrucha T, Smolewski P, Robak T, Chojnowski K. Plasma levels of angiogenic factors and circulating endothelial cells in essential thrombocythemia: correlation with cytoreductive therapy and JAK2-V617F mutational status. Leuk Lymphoma. 2010 Sep; 51(9): 1727-33.
  23. Robak T. Hairy-cell leukemia variant: recent view on diagnosis, biology and treatment. Cancer Treat Rev. 2011 Feb; 37(1): 3-10. Epub 2010 Jun 16. Review.
  24. Treliński J, Wierzbowska A, Krawczyńska A, Sakowicz A, Pietrucha T, Smolewski P, Robak T, Chojnowski K. Circulating endothelial cells in essential thrombocythemia and polycythemia vera: correlation with JAK2-V617F mutational status, angiogenic factors and coagulation activation markers. Int J Hematol. 2010 Jun; 91(5): 792-8. Epub 2010 May 15.
  25. Coiffier B, Losic N, Rønn BB, Lepretre S, Pedersen LM, Gadeberg O, Frederiksen H, van Oers MH, Wooldridge J, Kloczko J, Holowiecki J, Hellmann A, Walewski J, Robak T, Petersen J. Pharmacokinetics and pharmacokinetic/pharmacodynamic associations of ofatumumab, a human monoclonal CD20 antibody, in patients with relapsed or refractory chronic lymphocytic leukaemia: a phase 1-2 study. Br J Haematol. 2010 Jul; 150(1): 58-71.
  26. Robak T, Jamroziak K, Gora-Tybor J, Stella-Holowiecka B, Konopka L, Ceglarek B, Warzocha K, Seferynska I, Piszcz J, Calbecka M, Kostyra A, Dwilewicz-Trojaczek J, Dmoszyñska A, Zawilska K, Hellmann A, Zdunczyk A, Potoczek S, Piotrowska M, Lewandowski K, Blonski JZ. Comparison of cladribine plus cyclophosphamide with fludarabine plus cyclophosphamide as first-line therapy for chronic lymphocytic leukemia: a phase III randomized study by the Polish Adult Leukemia Group (PALG-CLL3 Study). J Clin Oncol. 2010 Apr 10; 28(11): 1863-9.
  27. Robak T, Dmoszynska A, Solal-Céligny P, Warzocha K, Loscertales J, Catalano J, Afanasiev BV, Larratt L, Geisler CH, Montillo M, Zyuzgin I, Ganly PS, Dartigeas C, Rosta A, Maurer J, Mendila M, Saville MW, Valente N, Wenger MK, Moiseev SI. Rituximab plus fludarabine and cyclophosphamide prolongs progression-free survival compared with fludarabine and cyclophosphamide alone in previously treated chronic lymphocytic leukemia. J Clin Oncol. 2010 Apr 1; 28(10): 1756-65.
  28. Robak T. Improving FCR immunochemotherapy in CLL. Blood. 2010 Jan 21; 115(3): 437-8.
  29. Pluta A, Wrzesien-Kus A, Cebula-Obrzut B, Wolska A, Szmigielska-Kaplon A, Czemerska M, Pluta P, Robak T, Smolewski P, Wierzbowska A. Influence of high expression of Smac/DIABLO protein on the clinical outcome in acute myeloid leukemia patients. Leuk Res. 2010 Oct; 34(10): 1308-13.
  30. Grzybowska-Izydorczyk O, Cebula B, Robak T, Smolewski P. Expression and prognostic significance of the inhibitor of apoptosis protein (IAP) family and its antagonists in chronic lymphocytic leukaemia. Eur J Cancer. 2010 Mar; 46(4): 800-10.
  31. Robak T. Application of new drugs in chronic lymphocytic leukemia. Mediterr J Hematol Infect Dis. 2010 May 10; 2(2): e2010011.
  32. Robak T, Robak P, Smolewski P. TRU-016, a humanized anti-CD37 IgG fusion protein for the potential treatment of B-cell malignancies. Curr Opin Investig Drugs. 2009 Dec; 10(12): 1383-90. Review.
  33. Robak T, Jamroziak K, Robak P. Current and emerging treatments for chronic lymphocytic leukaemia. Drugs. 2009; 69(17): 2415-49.
  34. Plewka M, Krzemińska-Pakuła M, Lipiec P, Peruga JZ, Jezewski T, Kidawa M, Wierzbowska-Drabik K, Korycka A, Robak T, Kasprzak JD. Effect of intracoronary injection of mononuclear bone marrow stem cells on left ventricular function in patients with acute myocardial infarction. Am J Cardiol. 2009 Nov 15; 104(10): 1336-42. Epub 2009 Sep 25.
  35. Liu JM, Gora-Tybor J, Grzybowska-Izydorczyk O, Bignon J, Robak T, Wdzieczak-Bakala J. Elevated plasma levels of the angiogenic tetrapeptide acetyl-ser-asp-lys-pro are found in some patients with hematologic malignancies. Leuk Lymphoma. 2009 Dec; 50(12): 2096-7.
  36. Treliński J, Tybura M, Smolewski P, Robak T, Chojnowski K. The influence of low-dose aspirin and hydroxyurea on platelet-leukocyte interactions in patients with essential thrombocythemia. Blood Coagul Fibrinolysis. 2009 Dec; 20(8): 646-51.
  37. Zolnierczyk JD, Błoński JZ, Robak T, Kiliańska ZM, Wesierska-Gadek J. Roscovitine triggers apoptosis in B-cell chronic lymphocytic leukemia cells with similar efficiency as combinations of conventional purine analogs with cyclophosphamide. Ann N Y Acad Sci. 2009 Aug; 1171: 124-31.
  38. Robak T. How to improve the treatment outcome in chronic lymphocytic leukemia? Leuk Res. 2010 Mar; 34(3): 272-5.
  39. Robak T, Salama A, Kovaleva L, Vyhovska Y, Davies SV, Mazzucconi MG, Zenker O, Kiessling P; International Privigen in ITP Study Group. Efficacy and safety of Privigen, a novel liquid intravenous immunoglobulin formulation, in adolescent and adult patients with chronic immune thrombocytopenic purpura. Hematology. 2009 Aug; 14(4): 227-36.
  40. Lech-Maranda E, Seweryn M, Giebel S, Holowiecki J, Piatkowska-Jakubas B, Wegrzyn J, Skotnicki A, Kielbinski M, Kuliczkowski K, Paluszewska M, Jedrzejczak WW, Dutka M, Hellmann A, Flont M, Zdziarska B, Palynyczko G, Konopka L, Szpila T, Gawronski K, Sulek K, Sokolowski J, Kloczko J, Warzocha K, Robak T. Infectious complications in patients with acute myeloid leukemia treated according to the protocol with daunorubicin and cytarabine with or without addition of cladribine.A multicenter study by the Polish Adult Leukemia Group (PALG). Int J Infect Dis. 2010 Feb; 14(2): e132-40. Epub 2009 Jul 5.
  41. Peruga J, Plewka M, Kasprzak J, Jezewski T, Wierzbicka A, Robak T, Krzemińska-Pakuła M. Intracoronary administration of stem cells in patients with acute myocardial infarction - angiographic follow-up. Kardiol Pol. 2009 May; 67(5): 477-84.
  42. Lech-Maranda E, Korycka A, Robak T. Clofarabine as a novel nucleoside analogue approved to treat patients with haematological malignancies: mechanism of action and clinical activity. Mini Rev Med Chem. 2009 Jun; 9(7): 805-12. Review.
  43. Robak T. Novel drugs for chronic lymphoid leukemias: mechanism of action and therapeutic activity. Curr Med Chem. 2009; 16(18): 2212-34. Review.
  44. Robak T. GA-101, a third-generation, humanized and glyco-engineered anti-CD20 mAb for the treatment of B-cell lymphoid malignancies. Curr Opin Investig Drugs. 2009 Jun; 10(6): 588-96.
  45. Harousseau JL, Martinelli G, Jedrzejczak WW, Brandwein JM, Bordessoule D, Masszi T, Ossenkoppele GJ, Alexeeva JA, Beutel G, Maertens J, Vidriales MB, Dombret H, Thomas X, Burnett AK, Robak T, Khuageva NK, Golenkov AK, Tothova E, Mollgard L, Park YC, Bessems A, De Porre P, Howes AJ; FIGHT-AML-301 Investigators. A randomized phase 3 study of tipifarnib compared with best supportive care, including hydroxyurea, in the treatment of newly diagnosed acute myeloid leukemia in patients 70 years or older. Blood. 2009 Aug 6; 114(6): 1166-73.
  46. Giebel S, Holowiecki J, Krawczyk-Kulis M, Jagoda K, Stella-Holowiecka B, Sadus-Wojciechowska M, Hellmann A, Dmoszynska A, Paluszewska M, Robak T, Konopka L, Seferynska I, Skotnicki AB, Kyrcz-Krzemien S. Impact of granulocyte colony stimulating factor administered during induction and consolidation of adults withacute lymphoblastic leukemia on survival: long-term follow-up of the Polish adultleukemia group 4-96 study. Leuk Lymphoma. 2009 Jun; 50(6): 1050-3.
  47. Wolska A, Lech-Maranda E, Robak T. Toll-like receptors and their role in hematologic malignancies. Curr Mol Med. 2009 Apr; 9(3): 324-35.